Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
Go back to Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 7.66 +0.25 (3.37%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.41 | 52 Week High | $9.23 | |||
| Open | $7.49 | 52 Week Low | $1.16 | |||
| Day High | $7.70 | P/E | N/A | |||
| Day Low | $7.46 | EPS | $-0.30 | |||
| Volume | 3,248,724 | |||||
